Viking Therapeutics, Inc. (VKTX) Nears Obesity Drug Breakthrough with Phase 3 VK2735 Trial

We recently compiled a list of 11 Best Future Stocks to Buy Now. Viking Therapeutics, Inc. stands third on our list.

Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage biopharma company developing treatments for metabolic and endocrine disorders, including obesity, NASH, and rare diseases like X-linked adrenoleukodystrophy (X-ALD). Its lead candidate, VK2735—a dual GLP-1/GIP receptor agonist- is now in Phase 3 VANQUISH trials for obesity and obesity with type 2 diabetes, following strong Phase 1 and 2 results demonstrating significant weight loss and safety, making it one of the best growth stocks in the biotech sector.

Viking Therapeutics, Inc. (NASDAQ:VKTX) has also completed enrollment in a Phase 2 trial for an oral version of VK2735, with top-line results expected in the second half of 2025. If successful, the oral formulation could offer a more convenient alternative to injectable obesity drugs.

The company is further expanding its pipeline with a novel amylin agonist program aimed at metabolic disorders, expecting to file an IND by Q4 2025. Additionally, VK2809, a thyroid hormone receptor beta agonist for NASH, has shown positive Phase 2b results. The business is also advancing VK0214 for X-ALD and other programs targeting lipid metabolism.

Viking Therapeutics, Inc. (VKTX) Nears Obesity Drug Breakthrough with Phase 3 VK2735 Trial

A scientist in the lab, researching the development of biopharmaceutical monoclonal antibody drugs.

With a robust pipeline and $808 million in cash (as of June 2025), Viking Therapeutics, Inc. (NASDAQ:VKTX) is well-positioned to fund upcoming milestones. The Phase 3 VK2735 trials and pending oral trial results are key near-term catalysts.

While we acknowledge the risk and potential of VKTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VKTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.